Research Hub cuts Geratherm Medical price target to EUR 4, maintains buy rating

PUBT · 1d ago
Research Hub cuts Geratherm Medical price target to EUR 4, maintains buy rating
  • Analyst research flagged weak H1 2026 trading at Geratherm, citing respiratory supply constraints, softer demand, order delays in the Middle East.
  • Inkubator-Systems rebounded strongly; product-mix shift supported gross margin, keeping gross profit stable despite revenue pressure.
  • Cost inflation pushed EBIT into loss; inventory build weighed on operating cash flow.
  • Management issued no quantitative FY26 guidance; analysts cut target price to EUR 4 from EUR 4.5.
  • BUY rating maintained, citing large cash reserves as downside protection while the group shifts toward a MedTech holding structure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geratherm Medical AG published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.